Latest Research
A cross-section of the Cancer3.AI database: the newest publication from each body region first, then the next one from each — so the review spans cancer types instead of running in blocks. Summaries are generated by Claude Sonnet (Anthropic) and link to the original publications.
Antibody therapeutics: A new era for EGFR-mutant NSCLC treatment.
Chen X, et al
A comprehensive review published in Biochimica et Biophysica Acta synthesizes the rapidly evolving landscape of antibody-based therapeutics designed to overcome acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC). The review covers monoclonal antibodies such as cetuximab and necitumumab, bispecific antibodies targeting EGFR and resistance pathways like MET, anti-angiogenic agents such as bevacizumab, and antibody-drug conjugates (ADCs) targeting HER2, HER3, and TROP2, which have demonstrated remarkable clinical efficacy in TKI-resistant settings. Emerging immunomodulatory strategies targeting the adenosine pathway (CD73), phagocytosis checkpoints (CD24), and complement regulatory proteins (CD55/CD59) are also examined, alongside next-generation ADCs and immune-engaging bispecific antibodies. Collectively, these antibody-based approaches are reshaping treatment for EGFR-mutant NSCLC, offering renewed hope for patients who have exhausted standard TKI options.
Biochimica et biophysica acta. Reviews on cancer
Source →
Performing right upper abdominal cytoreduction: anatomical planes, liver mobilization and occult spaces.
Ray MD, et al
A retrospective study of 205 patients who underwent cytoreductive surgery (CRS) with complete liver mobilization for ovarian and peritoneal surface malignancies at AIIMS New Delhi achieved optimal cytoreduction in 194 patients (94.6%), with right hepatic vein (RHV) injury occurring in only 9 cases (4.4%), predominantly among the first 100 cases in the series. Drawing from a cohort of 600 CRS procedures performed between January 2014 and December 2025, the study provides a structured anatomical roadmap for the technically demanding right upper abdomen, covering dissection of Morrison's pouch, Glisson's capsule, and the hepato-caval groove. A central clinical contribution is the introduction of "Ray's triangle" as a practical danger-zone framework that helps surgeons anticipate and prevent life-threatening injury to the right hepatic vein and inferior vena cava during complete liver mobilization. These findings are directly relevant to surgeons performing cytoreduction for advanced ovarian cancer and other peritoneal surface malignancies where achieving a CC-0 resection score is the principal determinant of long-term survival.
Journal of the Egyptian National Cancer Institute
Source →
Global Bibliometric Analysis of Post-Translational Modifications in Oral Squamous Cell Carcinoma.
Yang Y, et al
A global bibliometric analysis of 647 publications on post-translational modifications (PTMs) in oral squamous cell carcinoma (OSCC) reveals a sustained upward trend in research output, with China leading at 355 publications (46.16%), followed by Japan with 129 (16.78%) and the United States with 98 (12.74%). The study, based on a comprehensive Web of Science Core Collection search completed on January 14, 2026, identified that PTM-related research in OSCC has evolved from intracellular molecular mechanisms toward global regulation of the tumor microenvironment, with increasing focus on clinical translation. Current research frontiers center on therapeutic resistance, malignant progression, epithelial-mesenchymal transition (EMT), and patient survival, offering a roadmap for future investigations into targeted therapies and prognostic model development for OSCC patients.
International dental journal
Source →
The glioma metabolite, D-2-hydroxyglutarate (D-2-HG), reduces synaptic transmission and epileptiform bursts in neocortical slices.
Shao L, et al
Contrary to a widely held hypothesis, the glioma metabolite D-2-hydroxyglutarate (D-2-HG) does not promote seizures in brain tissue but instead reduces epileptiform burst frequency and suppresses excitatory synaptic transmission in neocortical slices. Using whole-cell patch-clamp electrophysiology, researchers tested acute bath application of D-2-HG (10 mM) on neocortical tissue preserving intact excitatory-inhibitory networks, finding that rather than depolarizing neurons or triggering seizure-like discharges, D-2-HG prolonged inter-burst intervals and diminished both mono- and poly-synaptic excitatory postsynaptic currents. This finding is clinically significant because approximately 80% of patients with IDH-mutant low-grade gliomas experience seizures, and nearly half of those cases are drug-refractory, meaning the assumed mechanism driving epilepsy in these patients must be reconsidered. The results challenge the glutamate-mimicry model and redirect the search for the true cause of seizures in this large population of glioma patients.
Experimental neurology
Source →
Management of Soft Tissue and Visceral Leiomyosarcomas.
Campos F, et al
An international expert panel has published a consensus-based review in JAMA Oncology on the diagnosis and management of leiomyosarcoma, a rare and heterogeneous malignant soft tissue neoplasm associated with substantial morbidity and mortality. In localized disease, complete surgical resection remains the cornerstone of treatment with site-specific perioperative strategies, while prospective data supporting neoadjuvant or adjuvant chemotherapy remain lacking and the role of radiotherapy varies across anatomic sites. In advanced disease, active systemic regimens include anthracycline-based and gemcitabine-based combinations, trabectedin, and tyrosine kinase inhibitors, though optimal sequencing beyond first-line therapy is undefined and emerging data suggest benefit from treatment continuation strategies and local therapies in oligometastatic settings. The panel identified integration of molecular profiling into routine diagnostic pathways as a key unmet need, and concluded that management requires a multidisciplinary, site-specific approach informed by limited but evolving evidence.
JAMA oncology
Source →